Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Related Citations for PubMed (Select 22999151)

1.

An evaluation framework for funding drugs for rare diseases.

Winquist E, Bell CM, Clarke JT, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D.

Value Health. 2012 Sep-Oct;15(6):982-6. doi: 10.1016/j.jval.2012.06.009.

PMID:
22999151
2.

Idursulfase for the treatment of mucopolysaccharidosis II.

Clarke LA.

Expert Opin Pharmacother. 2008 Feb;9(2):311-7. doi: 10.1517/14656566.9.2.311 . Review.

PMID:
18201153
3.

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).

Sohn YB, Cho SY, Park SW, Kim SJ, Ko AR, Kwon EK, Han SJ, Jin DK.

Orphanet J Rare Dis. 2013 Mar 18;8:42. doi: 10.1186/1750-1172-8-42.

4.

Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.

Marín LL, Gutiérrez-Solana LG, Fernández AT.

Pediatr Dermatol. 2012 May-Jun;29(3):369-70. doi: 10.1111/j.1525-1470.2011.01418.x. Epub 2011 Oct 13.

PMID:
21995841
5.

Idursulfase in Hunter syndrome treatment.

Zareba G.

Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Review.

PMID:
18174963
6.

First treatment for Hunter syndrome.

[No authors listed]

FDA Consum. 2006 Nov-Dec;40(6):5. No abstract available.

7.

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

Wraith JE.

Acta Paediatr Suppl. 2008 Apr;97(457):76-8. doi: 10.1111/j.1651-2227.2008.00661.x. Review.

PMID:
18339193
8.

Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, Eto Y, Orii T.

Mol Genet Metab. 2010 Jan;99(1):18-25. doi: 10.1016/j.ymgme.2009.08.006. Epub .

PMID:
19773189
9.

Application of a policy framework for the public funding of drugs for rare diseases.

Winquist E, Coyle D, Clarke JT, Evans GA, Seager C, Chan W, Martin J.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S774-9. doi: 10.1007/s11606-014-2885-y.

PMID:
25029973
10.
11.

First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).

Alcalde-Martín C, Muro-Tudelilla JM, Cancho-Candela R, Gutiérrez-Solana LG, Pintos-Morell G, Martí-Herrero M, Munguira-Aguado P, Galán-Gómez E.

Eur J Med Genet. 2010 Nov-Dec;53(6):371-7. doi: 10.1016/j.ejmg.2010.07.013. Epub 2010 Aug 10.

PMID:
20709629
12.

[Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].

Szegedi M, Molnár MJ, Boncz I, Kosztolányi G.

Orv Hetil. 2014 Nov 2;155(44):1735-41. doi: 10.1556/OH.2014.30031. Review. Hungarian.

13.

Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.

Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L, Vellodi A.

J Inherit Metab Dis. 2011 Jun;34(3):749-54. doi: 10.1007/s10545-011-9280-1. Epub 2011 Feb 16.

PMID:
21327479
14.

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).

Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A.

Genet Med. 2006 Aug;8(8):465-73. Erratum in: Genet Med. 2006 Sep;8(9):599. Wendt, Suzanne [corrected to Wendt, Susanne]; Puga, Antonio [corrected to Puga, Ana Cristina]; Conway, Ann Marie [corrected to Conway, Anne Marie].

PMID:
16912578
15.

Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.

Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC.

Mol Genet Metab. 2007 Jun;91(2):183-90. Epub 2007 Apr 24.

PMID:
17459751
16.

Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.

Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA.

Acta Paediatr Suppl. 2002;91(439):98-9. Review.

PMID:
12572850
17.

[High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].

de Souza MV, Krug BC, Picon PD, Schwartz IV.

Cien Saude Colet. 2010 Nov;15 Suppl 3:3443-54. Review. Portuguese.

18.

Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.

Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA; HOS investigators.

Mol Genet Metab. 2010 Oct-Nov;101(2-3):123-9. doi: 10.1016/j.ymgme.2010.06.011. Epub 2010 Jun 23.

PMID:
20638311
19.

Idursulfase: I2S, iduronato-2-sulfatase.

[No authors listed]

Drugs R D. 2006;7(4):254-8. Review. No abstract available.

PMID:
16784250
20.

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A.

Mol Genet Metab. 2007 Mar;90(3):329-37. Epub 2006 Dec 20.

PMID:
17185020
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk